Transition Bio Inks ~$500M Pact with Voyager Therapeutics to Develop Small Molecules for Neurodegenerative Diseases

Shots:Transition Bio has entered into a drug discovery collaboration & license option agreement with Voyager Therapeutics to identify & develop selective small molecules targeting TDP-43 pathology in amyotrophic lateral sclerosis (ALS) & frontotemporal dementiaAs per the deal, Transition Bio will discover & optimize TDP-43–targeting small molecules, after which Voyager may license exclusive global…

ByRidhi Rastogi2 days ago

NEWS

Amgen and Kyowa Kirin Report Topline P-III (ASCEND) Study Results of Rocatinlimab in Moderate to Severe Atopic Dermatitis

Shots:The P-III (ASCEND) trial evaluated rocatinlimab (150 or 300mg, Q4W/Q8W) in ~2,600 atopic dermatitis pts who completed 24wks. in ROCKET trial program & continued for 32wks. in ASCEND, which will evaluate long-term safety & efficacy up to 104wks.Trial showed a favorable long-term safety profile (1EP) with low discontinuation rates due to AEs, consistent…

ByRidhi RastogiSeptember 9, 2025

VIEWPOINTS

Avery Ince, VP, Medical Affairs – CVM Franchise, Janssen Shares his Views on New Data from P-III VOYAGER PAD Trial

Shots:Avery spoke about the study design and the new data obtained from the P-III VOYAGER PAD trial evaluating Xarelto + Aspirin to treat peripheral artery disease presented at the 72nd ACC 2023The data demonstrated that the treatment with the Xarelto vascular dose following LER had a 33% reduction in acute limb ischemia and a 15%…

BySenior EditorJune 5, 2023

Transition Bio Inks ~$500M Pact with Voyager Therapeutics to Develop Small Molecules for Neurodegenerative Diseases

Amgen and Kyowa Kirin Report Topline P-III (ASCEND) Study Results of Rocatinlimab in Moderate to Severe Atopic Dermatitis

Avery Ince, VP, Medical Affairs – CVM Franchise, Janssen Shares his Views on New Data from P-III VOYAGER PAD Trial

Contact US

OUR INFORMATION

FOLLOW US